Epidemiology studies are useful to clinicians because they highlight diagnosis and prescribing patterns, common trends within a disease, and unmet needs.
At the recent American Headache Society meeting, researchers detailed the manifold risks of opioid use in patients with migraine.
The latest advances in diagnosis and treatment are discussed in meeting presentations and recent studies and reviews.
MAST study results, remote electrical neuromodulation for acute treatment, and noninvasive vagus nerve stimulation are featured topics.
Because opioids have been shown to increase disability and reduce quality of life in patients with migraine, the search is on for effective alternative treatments.
Nearly one-third of persons with four or more migraine headache days per month have not received a diagnosis.
A promising alternative for patients who do not respond well to triptans or who wish to avoid pharmacotherapy.
Novel options for both acute and preventive therapy were presented at the American Headache Society Annual Scientific Meeting.
Emgality (galcanezumab-gnlm) is the first FDA-approved drug that reduces the frequency of headache attacks.
College athletes may be sabotaging their careers—as well as their performance—when they sacrifice sleep for sports, studying, and socializing.